Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Avidity Biosciences Inc. is a biopharmaceutical company developing Antibody Oligonucleotide Conjugates (AOCs™), a novel class of RNA therapeutics that combine the specificity of monoclonal antibodies with the precision of oligonucleotides to target hard-to-reach tissues like skeletal and cardiac muscle. This proprietary AOC platform enables targeted delivery of RNA-modulating therapies directly into cells, addressing the root causes of diseases previously challenging for existing RNA treatments. The company focuses on rare neuromuscular diseases, including myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral muscular dystrophy (FSHD), with multiple programs in clinical development. Avidity Biosciences Inc. also advances initiatives in precision cardiology and immunology through internal discovery efforts and partnerships. Headquartered in San Diego, California, the company operates within the pharmaceutical preparation manufacturing segment, emphasizing innovative solutions for patients with unmet medical needs in muscle disease franchises and beyond.
$12.33
+$0.16 (+1.31%)
EOD Aug 13, 2026
The business is unprofitable at the operating level (-412.58% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue grew 70.9%, still solid. Margins contracted 291.3pp, which offsets some of the top-line progress.
Negative free cash flow of -$43M. The business is consuming cash, not generating it. Operating margin contracted 291.3pp YoY, cost discipline may be slipping.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$36M
▲ +70.9% YoY
Net Income (TTM)
-$13M
▼ -205.2% YoY
Op. Margin
11.25%
▼ -291.3pp YoY
ROIC
-55.73%
▲ +69.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$8M
▼ -86.6% YoY
Op. Cash Flow (TTM)
-$19M
▼ -86.0% YoY
Net Debt
-$266M
Net Cash Position
Cash & Equiv.
$270M
3Y CAGR: +26.4%
Continue Research
Avidity Biosciences (RNA)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Avidity Biosciences scores 50/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Avidity Biosciences scores 50 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a 11.2% operating margin and a -55.7% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh RNA's valuation and scores 50/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.